Table 1 Baseline demographic data of patient cohort
Characteristics | N = 18 |
|---|---|
Gender, female | 16 (89%) |
Age, mean ± SD | 13,9 ± 2.9 years |
JIA subtype | |
Oligoarticular, persistent | 5 (28%) |
Oligoarticular, extended | 6 (33%) |
Polyarticular, rheumatoid-factor negative | 4 (22%) |
Psoriatic arthritis | 2 (11%) |
Enthesitis-associated arthritis | 1 (6%) |
Disease characteristics | |
ANA positive | 14/18 (78%) |
HLA-B27 positive | 4/18 (22%) |
Age at diagnosis, mean ± SD | 6.8 ± 4.4 years |
Disease duration, mean ± SD | 7.1 ± 4.1 years |
Medications | |
MTX route of administration, subcutaneous | 11/18 (61%) |
MTX duration use, mean ± SD | 59 ± 40 months |
MTX dose, mean ± SD | 12.3 ± 1.6 mg/sqm/week |
Additional medication | |
TNFα inhibitors | 7/18 (39%) |
NSAIDs, regularly | 2/18 (11%) |
Folic acid | 16/18 (89%) |